Metraipolis › archive › dc_365d02efb2bf

Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action — Europe PMC PMID:33647008

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/33647008
DOI
10.1371/journal.pcbi.1008752
License (as archived)
CC0-1.0
Archived
2026-11-05T19:09:11.899Z
SHA-256 of the archived text
a6977e396afdd256d99ca77ed85cfe6ea093ec62d28a5ef3558b655f3c469e55
Stable URL of this page
https://metraipolis.com/documento/dc_365d02efb2bf

How to cite

Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action — Europe PMC PMID:33647008 — Europe PMC (en), https://europepmc.org/article/MED/33647008 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_365d02efb2bf (Metraipolis archive dc_365d02efb2bf, sha256 a6977e396afdd256d99ca77ed85cfe6ea093ec62d28a5ef3558b655f3c469e55)
BibTeX
@misc{dc365d02efb2bf,
  title = {Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action — Europe PMC PMID:33647008},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/33647008},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_365d02efb2bf; sha256 a6977e396afdd256d99ca77ed85cfe6ea093ec62d28a5ef3558b655f3c469e55},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33647008. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Repurposed drugs that are safe and immediately available constitute a first line of defense against new viral infections. Despite limited antiviral activity against SARS-CoV-2, several drugs are being tested as medication or as prophylaxis to prevent infection. Using a stochastic model of early phase infection, we evaluate the success of prophylactic treatment with different drug types to prevent viral infection. We find that there exists a critical efficacy that a treatment must reach in order to block viral establishment. Treatment by a combination of drugs reduces the critical efficacy, most effectively by the combination of a drug blocking viral entry into cells and a drug increasing viral clearance. Below the critical efficacy, the risk of infection can nonetheless be reduced. Drugs blocking viral entry into cells or enhancing viral clearance reduce the risk of infection more than drugs that reduce viral production in infected cells. The larger the initial inoculum of infectious virus, the less likely is prevention of an infection. In our model, we find that as long as the viral inoculum is smaller than 10 infectious virus particles, viral infection can be prevented almost certainly with drugs of 90% efficacy (or more). Even when a viral infection cannot be prevented, antivirals delay the time to detectable viral loads. The largest delay of viral infection is achieved by drugs reducing viral production in infected cells. A delay of virus infection flattens the within-host viral dynamic curve, possibly reducing transmission and symptom severity. Thus, antiviral prophylaxis, even with reduced efficacy, could be efficiently used to prevent or alleviate infection in people at high risk.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS computational biology, 2021 (prima pubblicazione 2021-03-01).
Identificativi: PMID 33647008 · PMCID PMC7951973 · DOI 10.1371/journal.pcbi.1008752.
Descrittori MeSH principali: SARS-CoV-2; COVID-19 Drug Treatment.
Pagina: https://europepmc.org/article/MED/33647008 — https://doi.org/10.1371/journal.pcbi.1008752. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-05T19:03:16.979Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.